Early trials with FK 506 as primary treatment in liver transplantation.

PubWeight™: 3.29‹?› | Rank: Top 1%

🔗 View Article (PMC 2903882)

Published in Transplant Proc on February 01, 1990

Authors

S Todo1, J J Fung, A J Demetris, A Jain, R Venkataramanan, T E Starzl

Author Affiliations

1: Department of Surgery, University Health Center of Pittsburgh, University of Pittsburgh, PA.

Articles citing this

Kidney transplantation under FK 506. JAMA (1990) 7.45

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Transplantation. JAMA (1990) 1.71

Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41

A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18

The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc (1991) 1.16

Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. Transplant Proc (1991) 1.02

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Preliminary experience with FK506 in thoracic transplantation. Transplantation (1991) 0.97

Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93

Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation (2000) 0.92

Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc (1991) 0.87

FK 506 and autoimmune disease: perspective and prospects. Autoimmunity (1992) 0.85

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen. Drug Des Devel Ther (2014) 0.85

FK506 in solid organ transplantation. Ther Drug Monit (1995) 0.85

A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg (1996) 0.83

Renal dysfunction associated with liver transplantation. Postgrad Med J (1995) 0.83

Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg (1999) 0.81

Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. Clin Exp Immunol (1990) 0.81

Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc (1993) 0.81

Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo) (2015) 0.79

Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. Transplantation (1992) 0.78

Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation. Semin Plast Surg (2007) 0.76

Effect of renal ischemia on plasma levels of FK 506 in rats. Transplant Proc (1992) 0.75

Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75

In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol (1991) 0.75

Articles cited by this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Liver transplantation (1). N Engl J Med (1989) 4.53

Liver transplantation (2). N Engl J Med (1989) 2.93

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet (1986) 3.53

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24